Product Description
Pre-exposure prophylaxis (PrEP) is used for adults at risk of HIV-1 infection and adolescents weighing at least 35 kg. (Sourced from: https://www.cde.org.cn/main/xxgk/listpage/4b5255eb0a84820cef4ca3e8b6bbe20c)
Mechanisms of Action: HIV-1 Inhibitor
Novel Mechanism: Yes
Modality: Unknown
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Jiangsu Aidi Pharmaceutical
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: HIV Infections
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|